Home › RegulatorySummit Therapeutics Inc. - 10-Q FilingSummit Therapeutics Inc. reported a net loss for Q2 2026 due to continued R&D expenses.SEC EDGAR · July 23, 2026, 20:09 UTCTickers: $SMMT Read the full article at SEC EDGAR